Discover how our combination of nature and science is
Changing the Way Cancer is Treated
News
📣 ANZCTR Clinical Trial Update: IMMUNE‑12 Now Recruiting
We’re pleased to share that the Phase 2 clinical trial of IMMUNE‑12 for high‑grade gliomas (GBM) is actively recruiting participants at multiple sites in Australia...
Andrew Satterlee from UNC presented Immune 12 pre-clinical research at the 7th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies, held in conjunction with the 30th Society for Neuro-Oncology (SNO) Annual Meeting & Education Day in Honolulu, Hawaii. Nov. 19-23, 2025.
PMB attended the 7th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies, held in conjunction with the 30th Society for Neuro-Oncology Annual Meeting & Education Day in beautiful Honolulu, Hawaii! This year’s meeting was particularly special, as it marks SNO’s 30th anniversary—a milestone that underscores three decades of progress, collaboration, and innovation in neuro-oncology. The meeting took place Nov. 19-23, 2025.
We recently updated our projected timeline for US based clinical trials for Investigational Product Immune12 which will be done in association with our ongoing FDA reviews and approvals. Â
The 17th COGNO Annual Scientific Meeting (ASM), New Horizons, Novel Therapies, held from Sunday 14 to Tuesday 16 September 2025 at The Langham Gold Coast, Queensland, was a resounding success. The conference spotlighted cutting-edge treatments...
PMB participated in the LSX USA Congress in Boston on September 16–17, where we engaged in dynamic conversations around biotech innovation and next-generation therapeutics. The event provided a valuable platform to connect with leaders in oncology, biologics, and investment, fostering meaningful dialogue on the future of neuro-oncology.
We highlighted Immune12, our groundbreaking marine-sourced complex biologic targeting Glioblastoma (GBM), one of the most aggressive forms of brain cancer. The conference proved to be a productive opportunity to share insights, explore strategic collaborations, and advance our mission to transform outcomes for patients facing GBM.
PMB researchers shared results of pre-clinical evaluations of Immune-12 with industry and academia at the GBM Drug Development Summit. Immune-12 shows promising antitumor effects in various cancers, with ongoing pre-clinical evaluations at the University of North Carolina. ​
The study aims to evaluate the antitumor potency, characterize the makeup, and determine the mechanisms of Immune-12. ​